---
title: "VNDA: Fanapt® sales surged, BYSANTI™ gained FDA approval, and NEREUS™ launched in Q2 2026"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295007537.md"
description: "Fanapt® drove strong prescription growth in Q2 2026, while total net product sales declined 4% year-over-year due to HETLIOZ® timing. BYSANTI™ received FDA approval, NEREUS™ launched, and multiple late-stage clinical milestones are expected by year-end.Original document: Vanda Pharmaceuticals Inc. [VNDA] SEC 8-K Current Report — Aug. 5 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-08-05T20:10:12.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295007537.md)
  - [en](https://longbridge.com/en/news/295007537.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295007537.md)
generator: "portal-rs"
---

# VNDA: Fanapt® sales surged, BYSANTI™ gained FDA approval, and NEREUS™ launched in Q2 2026

Fanapt® drove strong prescription growth in Q2 2026, while total net product sales declined 4% year-over-year due to HETLIOZ® timing. BYSANTI™ received FDA approval, NEREUS™ launched, and multiple late-stage clinical milestones are expected by year-end.

Original document: Vanda Pharmaceuticals Inc. \[VNDA\] SEC 8-K Current Report — Aug. 5 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [VNDA.US](https://longbridge.com/en/quote/VNDA.US.md)

## Related News & Research

- [Vanda says EU grants orphan drug status to imsidolimab for generalized pustular psoriasis](https://longbridge.com/en/news/296776870.md)
- [Vanda Pharmaceuticals Q2 loss widens on lower sales, higher costs](https://longbridge.com/en/news/295007325.md)
- [AMD Surpasses $1 Tln Market Cap As AI Demand Drives Record Rally](https://longbridge.com/en/news/299684017.md)
- [Micron's (MU) AI Boom Could Outlast the Memory Cycle](https://longbridge.com/en/news/299769666.md)
- [Microsoft's Biggest AI Customer Is Also Its Biggest Risk](https://longbridge.com/en/news/299731848.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**